Stoke Therapeutics

Stoke Therapeutics

Stoke Therapeutics

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.
Type
B2b
Founded
2017
Raised
$40M
Follow us
Alexa global traffic share